Further to its announcement on 20 April that it had signed a Material Transfer Agreement (MTA) to provide manufacturing capacity for Mologic’s COVID-19 first generation ELISA diagnostics and CE marking on 27 April, Omega has signed a 3-year supply agreement for the ELISA tests as well as extended the collaboration to include the manufacture of an ELISA antigen test and two point-of-care (POC) lateral flow tests – both antigen and antibody tests – that are being developed by
09 Jun 2020
Omega Diagnostics - Additional Mologic agreement and trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Omega Diagnostics - Additional Mologic agreement and trading update
Cambridge Nutritional Sciences PLC (CNSL:LON) | 4.0 0 8.1% | Mkt Cap: 9.52m
- Published:
09 Jun 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
9
Further to its announcement on 20 April that it had signed a Material Transfer Agreement (MTA) to provide manufacturing capacity for Mologic’s COVID-19 first generation ELISA diagnostics and CE marking on 27 April, Omega has signed a 3-year supply agreement for the ELISA tests as well as extended the collaboration to include the manufacture of an ELISA antigen test and two point-of-care (POC) lateral flow tests – both antigen and antibody tests – that are being developed by